Results 41 to 50 of about 1,019 (188)

Spesolimab use in treatment of pyoderma gangrenosum

JAAD Case Reports, 2023
Sophie H. Guénin, MSc, Saakshi Khattri, MD, Mark G. Lebwohl, MD   +2 more
doaj   +3 more sources

Severe Acute Generalized Exanthematous Pustulosis Successfully Treated by Spesolimab

Acta Dermato-Venereologica
is missing (Short communication)
Giuseppe Russo, Shireen Dumont, Sébastien Menzinger, Damien Pastor, Laurence Toutous Trellu, Gürkan Kaya, Emmanuel Laffitte   +6 more
doaj   +4 more sources

Generalized pustular psoriasis successfully treated with spesolimab: A case report

SAGE Open Medical Case Reports
Generalized pustular psoriasis is defined as a primary, sterile, macroscopically visible pustular eruption on non-acral skin, which can occur with or without systemic inflammation and/or psoriasis vulgaris, and can either be relapsing or be persistent ...
Noemi Brigenti, Paolo Gisondi, Francesco Bellinato, Giampiero Girolomoni   +3 more
doaj   +4 more sources

Real-world Experience with Spesolimab in Chinese Patients with GPP

SKIN The Journal of Cutaneous Medicine
Generalized pustular psoriasis (GPP) is a heterogeneous, neutrophilic inflammatory disease associated with chronic skin and systemic symptoms, and potentially life-threatening flares. We present safety and efficacy data from a real-world expanded access program (EAP) in China (12 sites; May 2022–July 2023), which provided early access to spesolimab (an
Min Zheng, Furen Zhang, Yu-ling Shi, Xiaoming Liu, Aie Xu, Nichiren Pillai, Yuexiao Xu, Ada Chen, Rafael Sani Simoes, Xinghua Gao   +9 more
openaire   +2 more sources

Case report: A rollercoaster journey of pemphigus vegetans [PDF]

Frontiers in Immunology
Pemphigus vegetans (P Veg), the rarest subtype of pemphigus, is characterized by vegetative plaques, primarily affecting intertriginous areas. The most common autoantibodies target desmoglein 3 (Dsg3).
Xiaoyuan Hou, Jia Chen
doaj   +2 more sources

Long-term control of refractory acrodermatitis continua of Hallopeau with subcutaneous spesolimab: A case report [PDF]

JAAD Case Reports
Jan Nicolai Wagner, MD, Franziska Zirkenbach, MD, Brigtte Stephan, MD, Carolin Grote, MD, Matthias Augustin, Prof. Dr med   +4 more
doaj   +2 more sources

Rapid and sustained improvements in Generalized Pustular Psoriasis Physician Global Assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study [PDF]

, 2023
BACKGROUND: Effisayil 1 was a randomized, placebo-controlled study of spesolimab, which is an anti-IL-36 receptor antibody, in patients presenting with a generalized pustular psoriasis flare.
Anadkat, Milan J, Bachelez, Hervé, Barker, Jonathan, Elewski, Boni E, Ghoreschi, Kamran, Imafuku, Shinichi, Lebwohl, Mark G, Li, Ling, Mrowietz, Ulrich, Quaresma, Manuel, Thoma, Christian   +10 more
core   +2 more sources

Design of Effisayil™ 2: A randomized, double-blind, placebo-controlled study of spesolimab in preventing flares in patients with generalized pustular psoriasis [PDF]

, 2022
INTRODUCTION: Generalized pustular psoriasis (GPP) is a rare autoinflammatory skin disease characterized by flares of widespread erythema with sterile pustules, and can be relapsing with recurrent flares, or persistent with intermittent flares ...
Anadkat, Milan J, Bachelez, Hervé, Burden, A David, Choon, Siew Eng, Hua, Harry, Marrakchi, Slaheddine, Morita, Akimichi, Rajeswari, Sushmita, Thoma, Christian, Tsai, Tsen-Fang, Turki, Hamida, Zheng, Min   +11 more
core   +3 more sources

Psoriasis: talking points from recent clinical trials [PDF]

, 2022
Psoriasis is a chronic inflammatory skin disease that includes a wide spectrum of clinical variants. The most common form of psoriasis is chronic plaque psoriasis, which manifests as well- demarked, erythematous, and scaly plaques.
Bellinato, Francesco, Chiricozzi, Andrea, Gisondi, Paolo, Romita, Paolo   +3 more
core   +2 more sources

Efficacy and Safety of Spesolimab in Patients with Generalized Pustular Psoriasis: A Subgroup Analysis of Chinese Patients in the Effisayil 1 Trial

Dermatology and Therapy, 2023
Introduction Generalized pustular psoriasis (GPP) is a rare and potentially life-threatening skin disease. The global Effisayil 1 study investigated the efficacy and safety of spesolimab, a humanized monoclonal antibody targeting the IL-36 receptor, in ...
Tsen-Fang Tsai, Min Zheng, Yangfeng Ding, Zhiqi Song, Quanzhong Liu, Ying Chen, Hanzhao Hu, Jinhua Xu   +7 more
doaj   +1 more source